Physician profile
Michael Rowland
NPI 1992791081
$1,061.52
in general payments reported to CMS, 2019-2025
14 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $85.94 · 2023: $151 · 2024: $339 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $975.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $247.73 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $175.76 | 2023-2025 | Qulipta, Ubrelvy |
| Pfizer INC. | $121.55 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $105.46 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $85.94 | 2022 | |
| Lilly USA, LLC | $68.39 | 2023-2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $57.55 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $47.21 | 2024-2025 | Arexvy, Shingrix |
| Exact Sciences Corporation | $43.63 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astellas Pharma US INC | $35.06 | 2024 | Veozah |
| Si-Bone, INC. | $21.09 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.57 | 2025 | Caplyta |
| Alkermes, INC. | $16.80 | 2025 | Aristada, Lybalvi |
| Lundbeck LLC | $15.78 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rowland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.